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1. Introduction  
Glioma are a family of glial cell tumours of the central nervous system (CNS) well-
characterized as aggressive cancers with dismally limited treatment options. The relatively 
recent discoveries of mechanisms surrounding glioma cell antioxidant protection and 
neuronal and glial cell destruction have opened the gates to a new therapeutic avenue 
whose implications to the field of cancer biology extend far beyond the treatment of glioma 
alone. Stemming from the discovery of significant glutamate release and glutathione 
production by glioma cells, the mechanisms through which glioma mediate oxidative stress 
and influence their extracellular microenvironment are now being unravelled.  
This chapter will discuss the upregulation of the cystine/glutamate antiporter, system xc-, in 
glioma and the far ranging consequences that stem from this compensatory action. 
Specifically, a characteristic shift of cancer cell metabolism away from the tricarboxylic acid 
(TCA) cycle and towards increased rates of glycolysis, a process termed the Warburg effect, 
produces a high amount of reactive oxygen species (ROS) that would prove cytotoxic 
without adequate cellular antioxidant defences. In response to this metabolic abnormality, 
glioma have demonstrated increased synthesis of the primary cellular antioxidant 
glutathione and an increased circulation of the cystine/cysteine redox cycle. These 
antioxidant increases are driven by an upregulation of system xc-, which supplies the cell 
with the rate limiting substrate for glutathione synthesis, cysteine, and acts as one half of the 
transport machinery for the cystine/cysteine cycle. The increased tolerance to oxidative 
stress that is conferred by these mechanisms allows glioma survival and growth advantages 
and mediate chemo- and radiation-resistance to treatment. The corollary effect of cystine 
import via system xc- is the export of the neurotransmitter and ubiquitous cell-signalling 
molecule, glutamate. This release has destructive consequences for the peritumoral brain. 
Glutamate induces neuronal and glial excitotoxic cell death, and acts in an autocrine and 
paracrine signalling manner to stimulate glioma cell growth and migration. Treatments 
based on these mechanisms are currently under development and some have progressed as 
far as clinical trials. Glutamate receptor antagonists and system xc- inhibitors are as of yet the 
primary avenues of investigation. The potential treatment benefits of targeting these 
pathways are great, and the discovery of system xc- prevalence in other cancers beyond 
glioma suggests that study of this pathway may produce wide-ranging cancer treatment 
options. 
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2. Glioma metabolism and oxidative stress 
Cancer cells exist under self-induced conditions of abnormally elevated oxidative stress 
resulting from a characteristic shift in glucose metabolism away from the TCA cycle and 
towards a high rate of aerobic glycolysis (Kroemer & Pouyssegur, 2008). This metabolic shift 
results in less efficient ATP production from glucose by the cell, but serves to confer unique 
benefits upon the cancer cell allowing survival in conditions of high proliferation, high 
oxidative stress, and varying access to blood vasculature. One adaptive characteristic of 
cancer cells is the upregulation of antioxidant defence mechanisms, necessary for protection 
from the high level of ROS generated by escalated glycolysis.  
2.1 Cancer cell metabolism 
In normal cells, the metabolism of glucose generates ATP through glycolysis followed by a 
high rate of pyruvate metabolism through the TCA cycle. The final electron acceptor in the 
TCA cycle is oxygen, without which, the cycle ceases to function, and pyruvate is converted 
to lactate via anaerobic glycolysis (Kim & Dang, 2006). Anaerobic glycolysis is prevalent in 
hypoxic environments when the TCA cycle has no access to oxygen, however, glycolysis is 
also predominant in cancer cells even during aerobic conditions (Kim & Dang, 2006). This 
phenomenon of cancer cell metabolism was first described in the 1920s by Nobel laureate 
Otto Warburg and is to this day termed the Warburg effect, or aerobic glycolysis (Warburg 
et al., 1927). Most cancer cells, limited with regards to energy production by their shift away 
from the efficiency of the TCA cycle, rely upon an increased rate of glucose uptake for 
glycolytic ATP production. This allows the cell a number of advantages including the use of 
glycolytic intermediates for anabolic reactions, without which, rapidly proliferating cells in 
conditions of fluctuating oxygen availability could not survive (See review by Kroemer & 
Pouyssegur, 2008). All aerobic respiration generates ROS which induces oxidative damage 
within the cell (Balendiran et al., 2004). The enhanced metabolic activity of cancer cells raises 
ROS production to a level that demands adaptation by the cell to survive and proliferate 
despite the resulting high level of oxidative stress (Halliwell, 2007). The Warburg effect has 
been identified as a key factor in the increased oxidative stress that cancer cells face, and has 
also been directly implicated in the activation of oncogenes and the loss of tumour 
suppressor genes (Le et al., 2010). 
2.2 Glutathione synthesis response 
Glutathione (GSH) is a tripeptide thiol synthesized intracellularly from the amino acids 
glutamate, cysteine and glycine. In the cell it performs a number of functions, one of which 
is as the predominant cellular antioxidant in the body (Meister, 1995). GSH fulfils this role 
by acting as a substrate for several antioxidant enzymes as well as by acting directly upon 
free radicals in its reduced form, GSH, or in its oxidized form, glutathione disulfide 
(Meister, 1995). The rate-limiting step in GSH biosynthesis is the availability of cysteine, 
which in glioma cannot be synthesized intracellularly (Ishii et al., 1992). In glioma, increased 
oxidation of intracellular GSH and elevated oxidative stress induce the upregulation of 
cystine transport into the cell, allowing the dual processes of increased GSH biosynthesis, 
and increased cycling of the cystine/cysteine redox cycle, both of which counter the effects 
of ROS mediated damage (Banjac et al., 2008; Chung et al., 2005).  
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3. The System xc- antiporter and glioma 
In several cancers including glioma, cysteine must be obtained through the import of cystine 
from the extracellular environment. Cystine is imported into the cell via the system xc- 
cystine/glutamate antiporter; a transporter that is a feature of many cancer cell lines and 
endogenous to many tissues in the body. Cystine is the oxidized form of the amino acid, 
comprised of two cysteine molecules joined by a covalent double bond, and more prevalent 
in the oxidizing extracellular space. In the reducing environment of the cell, imported 
cystine is rapidly reduced to cysteine which is then incorporated as a substrate in GSH 
biosynthesis or serves to propel the cystine/cysteine redox cycle that plays a large role in 
maintaining extracellular redox balance (Ishii et al., 1992). The exported glutamate can have 
a number of deleterious effects upon the surrounding host tissue, many of which favour 
cancer cell survival and progression (Ishii et al., 1992).  
3.1 System xc- 
System xc- is the name given to the Na+ independent electroneutral exchanger of cystine and 
glutamate first described in human fibroblasts by Bannai & Kitamura (1980), and later 
named by Makowske & Christensen (1982). It is classified within the family of heteromeric 
amino acid transporters, all of which are comprised of a single heavy polypeptide subunit 
(SLC3 family) and a single light subunit (SLC7 family) coupled via a disulfide bridge 
(Chillarón et al., 2001). These transporters are essential for the import of amino acids to the 
cell that cannot be intracellularly synthesized. In system xc- the heavy subunit is 4F2hc 
(SLC3A2), a type II membrane glycoprotein common to many amino acid transporters 
(Verrey et al., 2004). It plays a regulatory role, functioning to traffic and adhere the 
transporter complex to the cell membrane. It features one transmembrane domain, and has a 
molecular weight of ~85 kDa (Lim & Donaldson, 2010). 4F2hc is not essential to the 
transport action of system xc- , and can be supplanted with another heavy chain polypeptide 
with similar transport and adherence capabilities, (ex. rBAT) without losing antiporter 
function (Wang et al., 2003). The light subunit of system xc- is xCT (SLC7A11), which is 
entirely responsible for the amino acid exchange function of the transporter and unique to 
system xc-. It features 12 transmembrane domains, and has a molecular weight of ~55 kDa 
(Lim & Donaldson, 2010). Cystine and glutamate are exchanged with a 1:1 stoichiometry 
that does not require an ionic gradient, rather it is thought that glutamate, which must be 
eliminated from the cytosol to prevent toxicity, provides the concentration gradient 
necessary for transporter function (Bannai & Ishii, 1988).  
3.1.1 System xc- in glia 
System xc- is expressed endogenously in a number of tissues in the body. In the human 
brain, it is a feature of both neurons and glial cells. Specifically, xCT was found to be 
expressed in neurons of the cerebral cortex, GFAP positive glial cells, vascular endothelial 
cells and the leptomeninges (Burdo et al., 2006). The prominence of system xc- in the brain is 
thought to be related to the organ’s relatively high rate of glucose metabolism and the need 
for antioxidants to protect highly sensitive neurons from the resulting ROS production 
(Conrad & Sato, 2011). The expression of xCT fluctuates greatly, and can be readily induced 
under a number of stimuli including low levels of extracellular cystine (Bannai & Kitamura, 
1982), and oxidative stress (Bannai et al., 1991). In astrocytes, the induced upregulation of 
xCT increased GSH synthesis and release and conferred antioxidant protection on immature 
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neurons in an in vitro co-culture model (Shih et al., 2006). Due to its critical role in 
maintaining antioxidant and glutamate balance, the misregulation of system xc- has the 
potential for great damage, and the transporter has been implicated in a number of CNS 
pathologies, including some characteristic features of morbidity in glioma.  
3.1.2 System xc- in glioma 
The ability of xCT to be readily induced upon exposure to oxidative stress or cysteine deficit 
is thought to be responsible for the presence of system xc- as a cell-culture induced artifact in 
some cell lines. In glioma cell lines this is not the case; system xc- has not only been 
demonstrated in established cell lines (Chung et al., 2005), but also in normal glia (Burdo et 
al., 2006), and in glioma tumour samples from patients (Lyons et al., 2007). 
In glioma, glucose metabolism is significantly escalated, as is characteristic of cancer cell 
metabolism. The resulting increase in the production of ROS from aerobic glycolysis induces 
the upregulation of xCT expression (Kim et al., 2001). With 4F2hc present in abundance, this 
xCT increase is sufficient to initiate an upregulation of system xc- characteristic of glioma 
(Sontheimer, 2008). The consequences of this system xc- upregulation are immensely 
detrimental to the patient as a result of both of the substrate actions of the antiporter. The 
greater import of cystine by system xc- allows the cell to survive and proliferate in conditions 
of oxidative stress that would be lethal to other cells. This increased resistance has a 
destructive outcome for the patient, allowing the glioma to survive and progress to a greater 
extent, and endowing the cell with resistance to cancer treatments, many of which attack 
cancer cells through increased oxidative stress. The simultaneous export of high levels of 
glutamate into the microenvironment of glutamate-sensitive brain tissues induces neuron 
and glial cell death and promotes the growth and migration of the tumour. These uniquely 
destructive outcomes from the action of system xc- ultimately aid the progression of the 
cancer. (See Fig. 1 concept model). 
4. System xc- and oxidative stress in glioma  
The upregulation of xCT readily occurs in response to oxidative stress. To mediate 
oxidative damage, the system xc- antiporter acts in two cystine-dependent manners to 
provide antioxidant capabilities to the cell and surrounding microenvironment. By 
increasing the availability of intracellular cysteine, this rate-limiting substrate is provided 
for both the synthesis of GSH, and for the completion of one half of the cystine/cysteine 
redox cycle. 
4.1 System xc- drives glutathione synthesis 
Within the cell, the tripeptide GSH is synthesized from its constituent amino acids, glycine, 
glutamate and cysteine via the enzymes -glutamylcysteine synthetase, adding glutamate; 
and glutathione synthetase, adding glycine in two steps (See Fig. 2). Oxidized GSH can be 
reduced back to its active form via glutathione reductase (Conrad & Sato, 2011). The rate-
limiting factor in this pathway is the availability of intracellular cysteine (Ishii et al., 1987). 
Most mammalian cells have the ability to directly import cysteine with a number of 
transporters (Lo et al., 2008), however cysteine is not prevalent in the extracellular space to 
the degree of cystine. Upon export from the cell, cysteine, the reduced and more prominent 
intracellular form of the amino acid, is rapidly oxidized to cystine, which is vastly more 
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Fig. 1. Summary concept model demonstrating the impact of altered cancer cell metabolism 
and cytotoxic treatments on cellular ROS, the upregulation of system xc-, and the consequent 
import of cystine and export of glutamate. Cystine import allows the synthesis of GSH and 
the cycling of the cystine/cysteine redox cycle. The export of glutamate has cytotoxic effects 
on brain cells within the tumour microenvironment, and autocrine and paracrine effects on 
the glioma initiating growth and increased migration.  
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Fig. 2. Glutathione biosynthesis and the cystine/cysteine redox cycle as driven by amino 
acid transporters in glioma. Glutamate is secreted by system xc- which requires both 
substrates to function. 
common in circulation (Bannai & Ishii, 1988). Not all cells possess the molecular machinery 
to import cystine, however, many brain cells and consequently, glioma with their high 
expression of system xc- and abundance of intracellular glutamate have both the mechanisms 
and the gradient to drive cystine transport. Once inside the cell, cystine is reduced to 
cysteine where it can be incorporated into polypeptide synthesis including the synthesis of 
GSH (Savaskan & Eyüpoglu, 2010). System xc- is one of many cystine transporters in the 
CNS, however it has been identified as the only cystine transporter expressed in glioma 
(Chung et al., 2005). Many cancers including glioma have demonstrated increased basal 
levels of intracellular GSH (Louw et al., 1997). Pharmacological inhibition of system xc-, and 
therefore limitation or elimination of available intracellular cysteine is able to deplete 
intracellular GSH almost entirely in a dose and time-dependent manner in glioma cell lines 
(Chung et al., 2005; Chung & Sontheimer, 2009; Pham et al., 2010). The negative effects of 
this GSH limitation on cell growth can be rescued entirely by the introduction of membrane 
permeable exogenous GSH, suggesting that cysteine availability for GSH production is 
critical for glioma cell growth (Chung & Sontheimer, 2009). 
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4.2 System xc- drives the cystine/cysteine redox cycle 
As cysteine is rate-limiting in GSH synthesis, it is well expected that increased availability of 
the amino acid from system xc- upregulation would have the observed positive impact on 
GSH levels. Increased cystine import in glioma has also been demonstrated to drive the 
cystine/cysteine redox cycle across the cell membrane, which acts independently of GSH to 
counter ROS. To cycle the amino acid , cystine is imported by system xc-, where it is 
promptly reduced in the cytoplasm, likely by GSH, and conversely cysteine is exported by 
the amino acid transporters system-L or system ASC to the extracellular environment where 
it is promptly oxidized (Conrad & Sato, 2011). It was discovered in xCT induced lymphoma 
cells that the cystine/cysteine cycle raised concentrations of extracellular cysteine and acted 
as an effective antioxidant even in cases of GSH depletion (Banjac et al., 2008). A subsequent 
study found that in cells negative for γ-glutamylcysteine synthetase and therefore unable to 
produce GSH, the cystine/cysteine cycle was sufficient to maintain oxidative stress 
protection (Mandal et al., 2010). This suggests that alternative redox systems can 
compensate for each other to the point of redundancy, and in this case, both cycles are 
driven by the import of cystine (Mandal et al., 2010). Both this redox cycle and GSH 
synthesis are enabled by the actions of system xc- and in glioma, both confer protection from 
oxidative stress to the cell.  
4.3 Consequences of ROS resistance 
The upregulation of antioxidant defences in glioma cells confers proliferation and survival 
benefits to glioma above those of normal cells without which, glioma could not thrive in their 
self-induced oxidative environment. The ability of glioma to upregulate antioxidant 
production in the face of ROS has long been suspected to contribute to the chemotherapy and 
radiation-resistance that is devastatingly common in the treatment of glioma, a condition 
already characterized by poor prognoses (Sontheimer, 2008). A large scale microarray to 
coordinate transporter gene expression in 60 cancer cell lines with the activity of 1400 
anticancer drugs revealed 39 drugs that positively correlate with SLC7a11 (xCT) expression 
and 296 that negatively correlate (Huang & Sadée, 2006). An example of a positively 
correlating drug is L-alanosine, an amino acid analogue whose uptake is mediated by system 
xc-. The authors demonstrated that pharmacologic system xc- inhibition reduced the efficacy of 
L-alanosine by impeding its system xc- mediated uptake. A negatively correlating drug is 
geldanamycin, an antibiotic that targets heat shock protein 90 (Hsp90). System xc- inhibition 
increased the efficacy of geldanamycin through a reduction of intracellular GSH which 
reduced cellular resistance to the drug’s cytotoxicity (Huang et al., 2005). Celastrol is another 
Hsp90 targeting drug that has demonstrated antitumoral properties specifically in glioma, and 
is also very negatively correlated with SLC7a11 expression (Huang et al., 2008). Inhibition of 
system xc- in celastrol-resistant glioma cells reduced chemoresistance to celastrol treatment, as 
did other negative modulators of GSH synthesis, indicating that celastrol resistance in glioma 
is at least in part mediated through the availability of GSH (Pham et al., 2010). 
5. System xc- and glutamate  
The corollary effect of system xc- mediated cystine uptake is the necessary secretion of 
glutamate into the extracellular space, without which system xc- cannot function. It has been 
demonstrated that glioma cells secrete amounts of glutamate via this mechanism that are 
significant enough to mediate excitotoxic cell death in the brain (Sontheimer, 2003; Takano 
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et al., 2001; Ye & Sontheimer, 1999). The amino acid glutamate is most well known as the 
primary excitatory neurotransmitter in the CNS, however it also functions as a growth 
factor and motogen to different cell types in the brain (de Groot & Sontheimer, 2010), and 
mediates critical cell signalling in many non-neuronal tissues (Hinoi et al., 2004).  
5.1 Glutamate release 
The normal brain usually does not harbour extracellular glutamate in excess of 1-3µM, likely 
due to the glutamate reuptake mechanisms of glia (de Groot & Sontheimer, 2010). In vitro, 
astrocyte cultures demonstrate the ability to reduce extracellular glutamate concentrations 
to near 1µM from 92µM within 3 hours, while conversely several glioma cell lines raised 
extracellular glutamate to 400-500µM in a 12-hour period (Ye & Sontheimer, 1999). When 
neurons were grown in co-culture or treated with media from independent glioma cultures, 
neurons died from glutamate-mediated excitotoxicity (Ye & Sontheimer, 1999). In normal 
brain, glutamate released into the extracellular space is rapidly removed, either back into the 
presynaptic nerve terminal, or, more commonly, by glial cells via one of the excitatory amino 
acid transporters (EAAT1 or EAAT2) (Danbolt, 2001). Glutamate reuptake is a key feature of 
normal glial cells that surround the synaptic cleft, a mechanism that contributes to neuron 
protection and signal consistency (de Groot & Sontheimer, 2010). It has been demonstrated 
by microarray that EAAT2 expression in glioma is negatively correlated with tumour 
progression, and that induction of glioma with EAAT2 expression dose-dependently limits 
cell growth, suggesting that the loss of EAAT function in glioma cells may play a role in the 
accumulation of extracellular glutamate (de Groot et al., 2005). Glutamate release from 
glioma was confirmed in vivo through glioma cells implanted into rat brain. Glutamate was 
measured to be highest in peritumoral regions, significantly higher than in the normal brain 
and the tumour itself (Behrens et al., 2000; Takano et al., 2001). Cells of the same type cloned 
as to not release glutamate grew significantly smaller tumours than their glutamate-
releasing counterparts (Takano et al., 2001). In glioma patients, despite conflicting reports, it 
appears that glutamate concentrations are significantly elevated in glioma in both the 
tumour (Behrens et al., 2000) and the peritumoural region (Roslin et al., 2003).  
5.2 Consequences of glutamate release 
Glutamate release into the peritumoral environment has a number of cytotoxic and cell 
signalling effects whose results are advantageous to glioma and seriously deleterious to the 
host. It has been suggested that glutamate release confers an adaptive advantage upon 
glioma (Sontheimer, 2003), but it is also possible that the release in great quantities of such a 
ubiquitous signalling molecule into a tissue that is highly sensitive to such molecules exerts 
a disruptive influence simply as a side-effect. This has also been demonstrated as a feature 
of glutamate-releasing cancers metastasized to bone, a tissue where glutamate is an 
important intercellular communication molecule (Seidlitz et al., 2010).  
Glioma exist in an environment physically constrained to the cavity of the cranium, a space 
consumed by 85% tissue and 15% cerebrospinal fluid (CSF). To grow, glioma must create 
space to occupy, as compression cannot occur in a vessel filled with fluid. Glutamate-
induced excitotoxic cell death is thought to be principally responsible for the clearance of 
brain cells along the tumour borders that allows glioma progression. Indicating the 
succeptability of brain tissues to glutamatergic disruption is that no cell type in the brain is 
without receptors for glutamate. The inhibition of system xc- in glioma significantly reduces 
extracellular glutamate levels, as well as neurodegeneration and cellular edema both in vitro 
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and in vivo, indicating the role of system xc- in the induction of these morbidities (Savaskan 
et al., 2008). Excitotoxicity is thought to be initiated as a result of excessive activation of 
glutamate receptors resulting in the uncontrolled increase of intracellular Ca2+ which 
stimulates the activation of cytotoxic enzymes (Choi, 1988). Neurons possess both the 
ionotropic α-amino-3-hydroxy-5-methyl-4-isoaxazolepropionate acid (AMPA) glutamate 
receptors, and N-methyl-D-aspartate (NMDA) glutamate receptors for excitatory glutamate 
signal transmission. Neurons in coculture and in vivo were shown to be highly sensitive to 
excitotoxic cell death when exposed to glutamate release from glioma (Takano et al., 2001). 
Treatment with the NMDA receptor antagonist MK801 reduced but did not entirely 
eliminate this excitotoxicity (Takano et al., 2001).  
Normal glial cells are also highly receptive to glutamate. Oligodendrocytes demonstrate a 
similar low tolerance to glutamate exposure as neurons, while astrocytes can tolerate much 
higher concentrations (Oka et al., 1993). Astrocytes normally function to remove glutamate 
from the extracellular space, so their tolerance to high glutamate concentrations is not 
surprising; however they too are eventually killed by an expanding glioma. Whether this 
cell death is also mediated by exposure to glutamate is not yet understood (de Groot & 
Sontheimer, 2010). 
It has also been reported that glutamate may have an autocrine or paracrine signalling effect 
on glioma cells. AMPA, NMDA, Kainate, and the metabotropic glutamate receptors mGluR3 
and mGLuR5 have all been identified in glioma, and growth-effects have been 
demonstrated through manipulation of both AMPA and NMDA receptors. Most glioma 
express AMPA receptors that are permeable to Ca2+ upon activation by glutamate (Ishiuchi 
et al., 2007). Induced expression of the GluR2 receptor subunit which renders AMPA 
receptors Ca2+ impermeable sensitized glioma cells to apoptosis and reduced tumour 
growth in vivo, suggesting the ability of glioma-derived glutamate signalling through 
AMPA receptors to act in an autocrine/paracrine manner to stimulate cell growth (Ishiuchi 
et al., 2007). 
Exogenous glutamate has a stimulatory effect on growth when applied to glioma cells, and 
conversely, antiproliferative effects on glioma have been demonstrated individually with 
several AMPA receptor antagonists and several NMDA receptor antagonists (Rzeski et al., 
2001). Inhibition of mGlu2/3 receptors with the antagonist LY341495 in glioma cells positive 
for both receptors also was able to reduce glioma cell growth both in vitro and in vivo 
(Arcella et al., 2005). Taken together, these results obtained through the blockade of nearly 
all glutamate receptors expressed in glioma suggest a significant autocrine/paracrine effect 
on growth of glioma-derived glutamate. 
6. Experimental therapeutics 
The myriad consequences originating from the upregulation of xCT in glioma have 
uncovered several novel possibilities for treatment of glioma. Any therapeutic targeting of 
the mechanisms of antioxidant production and glutamate release could prove to be critical 
in the treatment of glioma, as current therapies are limited in efficacy and often become 
redundant through acquired cell-resistance (Sontheimer, 2008). Symptom management may 
also arise from treating glutamate release, as it is hypothesized that frequent seizures, a 
morbidity that affects over 80% of glioma sufferers could be related to glutamate-induced 
hyperexcitability in the CNS, possibly in advance of neuron excitotoxic death and possibly 
an early indication of the cancer (de Groot & Sontheimer, 2010). 
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6.1 Targeting glutamate receptors 
AMPA receptor targeting has emerged as the most prolific avenue of interest for treatment 
from glioma glutamate-release work. An AMPA antagonist called talampanel is currently 
the most likely candidate for glioma treatment in this manner in large part because it does 
not exhibit the side-effects of most glutamate receptor antagonists in the CNS, and it has 
been shown to increase the lifespan of mice xenografted with human glioma (Goudar et al., 
2004). Two clinical trials have developed from these findings. The first, begun in 2009, was a 
phase II trial designed to examine the efficacy of talampanel in conjunction with standard 
radiation and temozolomide treatments in improving survival in adults with newly 
diagnosed glioblastoma (Grossman et al., 2009). This trial concluded that patients treated 
with talampanel demonstrated significantly longer survival than those who received 
standard care alone (Grossman et al., 2010). While this is promising and certainly demands 
further investigation, this study alone cannot be deemed conclusive. The second trial, a 
smaller phase II trial, examined the effects of talampanel alone on 6-month survival of 
patients with recurrent malignant glioma (Iwamoto et al., 2010). This trial determined that 
talampanel alone conferred no obvious advantage on patient survival, but the drug was 
tolerated well with no severe side-effects (Iwamoto et al., 2010). 
Inhibitors of other glutamate receptors have not yet been clinically evaluated, however the 
preliminary success of animal models of glioma treatment as mentioned above will certainly 
lead to trials of other glutamate receptor antagonists in the near future. Significant promise 
is held by these inhibitors as both candidate adjuvant therapies capable of supplementing 
treatment cytotoxicity or of mediating the effects of glutamate on the brain.  
6.2 System xc- Inhibition 
While the above-mentioned therapies for mediating the excess glutamate released by glioma 
are promising, certainly the most attractive potential therapies to arise from these studies 
are those that involve the inhibition of system xc-. Rather than mediate the consequences of 
destructive glutamate release and treatment-resistance, system xc- inhibition could eliminate 
the function of the transporter responsible for the excess glutamate, and consequently limit 
the multiple morbidities of glutamate release rather than manage its downstream effects. In 
addition, system xc- inhibition would limit cysteine availability to the glioma cell and 
therefore inhibit its antioxidative capabilities by way of both limiting glutathione synthesis 
and halting the drive of the cystine/cysteine redox cycle. There are many chemical 
inhibitors of system xc-; of these, the cyclic glutamate analogue S-(4)-carboxyphenylglycine 
has emerged as the most potent inhibitor (Patel et al., 2004), and the FDA approved anti-
inflammatory drug sulfasalazine has garnered the most clinical interest. Sulfasalazine has 
been demonstrated in animal models to effectively slow the growth of glioma and reduce 
levels of both intracellular GSH and extracellular glutamate (Chung et al., 2005; Chung & 
Sontheimer, 2009). A phase I clinical trial of sulfasalazine to evaluate drug safety and effects 
on tumour growth in the treatment of grade 3 glioma in a small number of patients was 
prematurely terminated due to several adverse effects during treatment (Robe et al., 2009; 
2006). This study was initiated on the basis on sulfasalazine acting as an inhibitor of NFkB, 
however treatment did not differ from that required for system xc- inhibition. Although the 
poor outcomes from this trial are unfortunate, they do little to dampen the potential of 
sulfasalazine for glioma treatment or system xc- as a therapeutic target. Another phase I 
clinical trial has just recently been initiated with the intent to examine the effects of 
sulfasalazine on glutamate release in the brain, and on seizures in low-grade, newly-
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diagnosed glioma patients (de Groot & Sontheimer, 2010). The upcoming results of this trial 
will be the first clinical evidence of treatments directed at system xc- inhibition, and will 
contribute greatly to the establishment of the role of this critical transporter in glioma 
morbidity and treatment. 
7. Conclusion 
Glioma exist in conditions of high oxidative stress as a result of the metabolic shift away 
from the TCA cycle and towards increased rates of glycolysis. This metabolic shift, the 
Warburg effect, is characteristic of cancer cells and confers unique benefits to the cell which 
allow survival and proliferation in conditions of rapid growth, division and variable access 
to blood vasculature. However, a result of this reliance on glycolysis is the increased 
prevalence of ROS in the cancer cell. To survive these conditions, cancer cells must possess 
upregulated mechanisms of antioxidation. Glioma exhibit an oxidative stress-mediated 
upregulation of the xCT coding gene SLC7a11, which, along with the membrane-anchoring 
protein 4F2hc comprise the two subunits of the Na+ independent electroneutral 
cystine/glutamate antiporter called system xc-. This antiporter drives the molecular turnover 
that is ultimately responsible for several of the features of morbidity in glioma, as well as its 
characteristic chemo- and radiation-resistance. The import of cystine into the cell increases 
the availability of cysteine for the GSH synthesis pathway and for the cystine/cysteine 
redox cycle. These two antioxidant pathways function to relieve the glioma cell of 
significant oxidative stress, allowing increased proliferation and survival of the cancer cells. 
This also allows resistance of glioma to oxidative stress-inducing radiation and 
chemotherapies. Conversely, the export of glutamate results in the neurotoxic death of 
neurons and glial cells in the vicinity of the tumour, and acts in an autocrine/paracrine 
manner to stimulate glioma proliferation and migration. Therapies are currently under 
development with these mechanisms in mind. Glutamate receptor antagonists have been 
demonstrated to limit brain cell death and to inhibit tumour growth in vitro and in xenograft 
animal models of glioma. System xc- inhibitors that prevent the import of cystine for 
antioxidant purposes and also prevent the release of glutamate into the extracellular 
environment have also demonstrated success in vitro and in vivo, and a clinical trial is 
currently underway with the inhibitor sulfasalazine. This work opens new pathways for 
investigation in a condition well known for poor prognoses and limited treatment options. 
The evidence of system xc- in other cancers in addition to glioma suggests that this 
mechanism may soon become of great importance to cancer treatment. 
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